Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.426
I. Oterino Moreira, BM Escudero Vilaplana, G. Silva Riádigos, CM Meseguer Barros, G. Picazo Sanchiz, L. Jamart Sanchez, S. Sanz Márquez, M. Pérez Encinas
Background and importanceThe characteristics of the patient who requires health care are different between primary care (PC) and hospital care (HC). The COVID-19 pandemic has impacted on public access to health services. Therefore, prescribing patterns and consumption of antimicrobials in both contexts could have changed.Aim and objectivesTo assess the impact of the COVID-19 pandemic on antimicrobial consumption in PC and HC.Material and methodsDescriptive cross-sectional study that evaluated the antimicrobial consumption (ATC J01) in adult patients 1 year before (March 2019–February 2020) and 1 year after (March 2020–February 2021) the arrival of the COVID-19 pandemic.Antimicrobial consumption rates were expressed in defined daily doses per 1000 inhabitants-day (DID). In PC we included the reference population of our area and in HC the number of patients discharged. The impact was assessed by the difference in DID between both periods and care settings.Data on antimicrobial prescribing in PC were obtained from a public database with anonymised data on the total number of items of each drug prescribed. Hospital data were obtained from the clinical unit of pharmacy.ResultsBetween March 2020 and February 2021 antimicrobial consumption decreased –36.0% (7.3 vs 11.4 DID) in PC and increased +37.5 (16.5 vs 12.0 DID) in HC, both compared to the same period of the previous year.The most prescribed antimicrobials in PC before the COVID-19 pandemic were amoxicillin, amoxicillin/clavulanate, doxycycline, azithromycin, ciprofloxacin, and between March 2020 and February 2021 these were amoxicillin/clavulanate, amoxicillin, doxycycline, ciprofloxacin and azithromycin.The most prescribed antimicrobial used in HC before the COVID-19 pandemic were amoxicillin/clavulanate, levofloxacin, piperacillin/tazobactam, ceftriaxone and ciprofloxacin, and between March 2020 and February 2021 these were amoxicillin/clavulanate, ceftriaxone, azithromycin, piperacillin/tazobactam and meropenem.Comparing the COVID period with the previous year, in PC the antimicrobial that most decreased in consumption was phenoxymethylpenicillin (–66.59%). Amoxicillin decreased by –52.13%, clarithromycin (–50.60%), moxifloxacin (–45.98%), levofloxacin (–44.42%), amoxicillin/clavulanate (–35.55%) and azithromycin (–29.05%). For HC the antimicrobial that most increased in consumption was azithromycin (+721.42%), followed by amoxicillin (+602.0%), ceftriaxone (+184.34%), vancomycin (+116.9%) and amikacin (+88.79%). Meropenem DID increased by +52.94%.Conclusion and relevanceThe COVID-19 pandemic has impacted on the increase in antimicrobial use in HC along with a proportional decrease in PC.Antimicrobial prescription patterns in PC remain stable. The increase in amoxicillin/clavulanate over amoxicillin may be related to non-contact patient care (telemedicine).In HC, antimicrobial stewardship strategies can help return the consumption of broad-spectrum antibiotics to acceptable levels.References a
{"title":"5PSQ-120 Impact of the COVID-19 pandemic on the use of antimicrobials in primary and hospital care","authors":"I. Oterino Moreira, BM Escudero Vilaplana, G. Silva Riádigos, CM Meseguer Barros, G. Picazo Sanchiz, L. Jamart Sanchez, S. Sanz Márquez, M. Pérez Encinas","doi":"10.1136/ejhpharm-2022-eahp.426","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.426","url":null,"abstract":"Background and importanceThe characteristics of the patient who requires health care are different between primary care (PC) and hospital care (HC). The COVID-19 pandemic has impacted on public access to health services. Therefore, prescribing patterns and consumption of antimicrobials in both contexts could have changed.Aim and objectivesTo assess the impact of the COVID-19 pandemic on antimicrobial consumption in PC and HC.Material and methodsDescriptive cross-sectional study that evaluated the antimicrobial consumption (ATC J01) in adult patients 1 year before (March 2019–February 2020) and 1 year after (March 2020–February 2021) the arrival of the COVID-19 pandemic.Antimicrobial consumption rates were expressed in defined daily doses per 1000 inhabitants-day (DID). In PC we included the reference population of our area and in HC the number of patients discharged. The impact was assessed by the difference in DID between both periods and care settings.Data on antimicrobial prescribing in PC were obtained from a public database with anonymised data on the total number of items of each drug prescribed. Hospital data were obtained from the clinical unit of pharmacy.ResultsBetween March 2020 and February 2021 antimicrobial consumption decreased –36.0% (7.3 vs 11.4 DID) in PC and increased +37.5 (16.5 vs 12.0 DID) in HC, both compared to the same period of the previous year.The most prescribed antimicrobials in PC before the COVID-19 pandemic were amoxicillin, amoxicillin/clavulanate, doxycycline, azithromycin, ciprofloxacin, and between March 2020 and February 2021 these were amoxicillin/clavulanate, amoxicillin, doxycycline, ciprofloxacin and azithromycin.The most prescribed antimicrobial used in HC before the COVID-19 pandemic were amoxicillin/clavulanate, levofloxacin, piperacillin/tazobactam, ceftriaxone and ciprofloxacin, and between March 2020 and February 2021 these were amoxicillin/clavulanate, ceftriaxone, azithromycin, piperacillin/tazobactam and meropenem.Comparing the COVID period with the previous year, in PC the antimicrobial that most decreased in consumption was phenoxymethylpenicillin (–66.59%). Amoxicillin decreased by –52.13%, clarithromycin (–50.60%), moxifloxacin (–45.98%), levofloxacin (–44.42%), amoxicillin/clavulanate (–35.55%) and azithromycin (–29.05%). For HC the antimicrobial that most increased in consumption was azithromycin (+721.42%), followed by amoxicillin (+602.0%), ceftriaxone (+184.34%), vancomycin (+116.9%) and amikacin (+88.79%). Meropenem DID increased by +52.94%.Conclusion and relevanceThe COVID-19 pandemic has impacted on the increase in antimicrobial use in HC along with a proportional decrease in PC.Antimicrobial prescription patterns in PC remain stable. The increase in amoxicillin/clavulanate over amoxicillin may be related to non-contact patient care (telemedicine).In HC, antimicrobial stewardship strategies can help return the consumption of broad-spectrum antibiotics to acceptable levels.References a","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131136351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.425
C. Şanlıoğlu, B. Sitter, I. Lagoja, W. Oczenski
Background and importanceProinflammatory cytokines seem to have an influence on the course and severity of a COVID-19 infection. The use of high-dose vitamin C (HDVC) represents a possible adjunctive therapy approach for the treatment of critically ill COVID-19 patients owing to its immune-modulating, anti-inflammatory and antioxidant properties.Aim and objectivesTo determine the impact of adjunctive HDVC therapy on inflammatory markers such as interleukin-6 (IL-6).Material and methodsSetting: A descriptive, retrospective analysis with critically ill COVID-19 patients admitted to the intermediate care unit (IMCU) and intensive care unit (ICU) in a public hospital.Adult ICU-hospitalised patients with COVID-19 were included with those who were to receive, besides the standard of care, either: HDVC (treatment group with 7.5 g/day VC up to 10 days)Low-dose VC (LDVC with 1g/day VC up to 10 days)No additional VC (control group).All data were obtained from the patients’ medical records from November to December 2020 and from March to May 2021.ResultsData were collected from 83 critically ill patients with confirmed COVID-19 infection. 40 patients were administered HDVC, 24 patients received LDVC and 19 patients did not receive any VC.The mean age of the patients in the treatment group was 57.3 years, in the LDVC group 62.1 years and in the control group 55.8 years. The average IMCU and ICU length of stay was 17.4 days for patients in the HDVC-group, 21.4 days in the LDVC-group and 21.5 days in the control group. 68% from the HDVC group survived and were discharged from hospital. In the LDVC group 58% survived and in the control group 42%. Lower levels of IL-6 in the HDVC-group as compared with the LDVC-group and control group were detected.Conclusion and relevanceOur findings have demonstrated that the use of HDVC can lead to a clinical benefit due to decreased levels of IL-6. Additional investigations should be encouraged in order to further characterise adjunctive HDVC treatment in COVID-19 infection. Unlike some previous studies, our results have shown no detrimental effects of HDVC on glomerular filtration rate and serum creatinine levels.References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"5PSQ-119 A descriptive, retrospective analysis of high-dose intravenous vitamin C administration in critically ill COVID-19 patients","authors":"C. Şanlıoğlu, B. Sitter, I. Lagoja, W. Oczenski","doi":"10.1136/ejhpharm-2022-eahp.425","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.425","url":null,"abstract":"Background and importanceProinflammatory cytokines seem to have an influence on the course and severity of a COVID-19 infection. The use of high-dose vitamin C (HDVC) represents a possible adjunctive therapy approach for the treatment of critically ill COVID-19 patients owing to its immune-modulating, anti-inflammatory and antioxidant properties.Aim and objectivesTo determine the impact of adjunctive HDVC therapy on inflammatory markers such as interleukin-6 (IL-6).Material and methodsSetting: A descriptive, retrospective analysis with critically ill COVID-19 patients admitted to the intermediate care unit (IMCU) and intensive care unit (ICU) in a public hospital.Adult ICU-hospitalised patients with COVID-19 were included with those who were to receive, besides the standard of care, either: HDVC (treatment group with 7.5 g/day VC up to 10 days)Low-dose VC (LDVC with 1g/day VC up to 10 days)No additional VC (control group).All data were obtained from the patients’ medical records from November to December 2020 and from March to May 2021.ResultsData were collected from 83 critically ill patients with confirmed COVID-19 infection. 40 patients were administered HDVC, 24 patients received LDVC and 19 patients did not receive any VC.The mean age of the patients in the treatment group was 57.3 years, in the LDVC group 62.1 years and in the control group 55.8 years. The average IMCU and ICU length of stay was 17.4 days for patients in the HDVC-group, 21.4 days in the LDVC-group and 21.5 days in the control group. 68% from the HDVC group survived and were discharged from hospital. In the LDVC group 58% survived and in the control group 42%. Lower levels of IL-6 in the HDVC-group as compared with the LDVC-group and control group were detected.Conclusion and relevanceOur findings have demonstrated that the use of HDVC can lead to a clinical benefit due to decreased levels of IL-6. Additional investigations should be encouraged in order to further characterise adjunctive HDVC treatment in COVID-19 infection. Unlike some previous studies, our results have shown no detrimental effects of HDVC on glomerular filtration rate and serum creatinine levels.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134242586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.423
M. Aguar Carrascosa, Á. S. García, I. Lara Cantón, A. García Robles, A. Cruz Sánchez, J. P. Poveda Andrés, A. Pinilla González, A. Illana
Figure. Pareto diagram. MATERIALS AND METHODS: experimental study to determinate which variable most influences the concentration and dose of insulin administrated. 24 experimental infusions were made, using combinations of different variables: additive (albumin yes/no), solvent (NaCl 0,9%/D5%) operator (1/2), pre-conditioning (yes/no), purge (yes/no), concentration (0.05-0.1 UI/mL), infusion rate (0.3-0.7mL/h) and infusion duration (1h/24h).
{"title":"5PSQ-105 Insulin perfusion in neonatology: which one is the safest?","authors":"M. Aguar Carrascosa, Á. S. García, I. Lara Cantón, A. García Robles, A. Cruz Sánchez, J. P. Poveda Andrés, A. Pinilla González, A. Illana","doi":"10.1136/ejhpharm-2022-eahp.423","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.423","url":null,"abstract":"Figure. Pareto diagram. MATERIALS AND METHODS: experimental study to determinate which variable most influences the concentration and dose of insulin administrated. 24 experimental infusions were made, using combinations of different variables: additive (albumin yes/no), solvent (NaCl 0,9%/D5%) operator (1/2), pre-conditioning (yes/no), purge (yes/no), concentration (0.05-0.1 UI/mL), infusion rate (0.3-0.7mL/h) and infusion duration (1h/24h).","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133666385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.389
R. Tamayo Bermejo, L. Yunquera Romero, M. Nieto Guindo, I. Muñoz Castillo
{"title":"4CPS-073 Desensitisation to ibrutinib in a patient with serious late reaction: a case report","authors":"R. Tamayo Bermejo, L. Yunquera Romero, M. Nieto Guindo, I. Muñoz Castillo","doi":"10.1136/ejhpharm-2022-eahp.389","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.389","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130144910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.416
A. Viney, M. Pereda Molina, AC Llamas Vallejo, IM Sánchez Pérez, MB Pereda Hernández, EV Sedamanos Saca, V. García Bordalás, J. P. Pérez Moreno, V. Contreras Rivera, M. Calero Martínez
{"title":"4CPS-272 Integration of the hospital pharmacist into a multidisciplinary dysphagia screening team in an intermediate and long-stay hospital","authors":"A. Viney, M. Pereda Molina, AC Llamas Vallejo, IM Sánchez Pérez, MB Pereda Hernández, EV Sedamanos Saca, V. García Bordalás, J. P. Pérez Moreno, V. Contreras Rivera, M. Calero Martínez","doi":"10.1136/ejhpharm-2022-eahp.416","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.416","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121847835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.415
T. Rovira, M. de Castro Julve, T. Gili Bigatà, G. Gómez Llanes, Y. Campos García, G. Molas Ferrer, B. López García, M. Gómez-Valent
{"title":"4CPS-265 Chronic complex palliative paediatric patient at-home care unit: pharmacotherapeutic profile and analysis of sialorrhea treatment","authors":"T. Rovira, M. de Castro Julve, T. Gili Bigatà, G. Gómez Llanes, Y. Campos García, G. Molas Ferrer, B. López García, M. Gómez-Valent","doi":"10.1136/ejhpharm-2022-eahp.415","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.415","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123768630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.378
A. Bayen, A. Nourddine, L. Zarayby, S. Derfoufi
{"title":"2SPD-022 Relevance of universal kit composition and economic value of non-used medical devices","authors":"A. Bayen, A. Nourddine, L. Zarayby, S. Derfoufi","doi":"10.1136/ejhpharm-2022-eahp.378","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.378","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126445188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.375
A. Alasseri, M. Manna
1ISG-009 Figure 1ResultsThe Pharmacy Department has the capacity to switch all outpatient prescriptions to be requested through the online portal and a total of 14 618 medication shipments were home delivered from 15 March to 10 June 2020. 14 618 medication shipments were delivered out of 25 520 online requests submitted;the difference between the number of delivered prescriptions and received requests was due to repeated submissions by patients or because the refill due date did not arrive.WhatsApp Business has been initiated for direct communication between patients and pharmacists. A total of 10 030 inpatient pharmacy and outpatient pharmacy orders were verified through remote access. 1ISG-009 Table 1Parameter Online refill March 2020 3340 April 2020 9413 May 2020 4990 10 June 2020 7777 Total number of requests during 2019 488 Total number of requests in 2020 25 520 Total shipped 15 March to 10 June 2020 14 618 WhatsApp sent message 14 633 WhatsApp received message 26 613 Orders verified by remote access (outpatient) 4650 Orders verified by remote access (inpatient) 5380 Conclusion and relevanceIn conclusion, the implementation of telepharmacy via the utilisation of medication home delivery services, remote access, and modification of the previous workflow was associated with promising outcomes in terms of efficient, high-quality pharmaceutical care delivery while avoiding medication distribution disturbances as well as containing the spread of the pandemic among staff and patients, thus ensuring their safety during this crisis.References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"1ISG-009 Implementation and evaluation of telepharmacy during the COVID-19 pandemic in an academic medical city: paving the way for telepharmacy","authors":"A. Alasseri, M. Manna","doi":"10.1136/ejhpharm-2022-eahp.375","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.375","url":null,"abstract":"1ISG-009 Figure 1ResultsThe Pharmacy Department has the capacity to switch all outpatient prescriptions to be requested through the online portal and a total of 14 618 medication shipments were home delivered from 15 March to 10 June 2020. 14 618 medication shipments were delivered out of 25 520 online requests submitted;the difference between the number of delivered prescriptions and received requests was due to repeated submissions by patients or because the refill due date did not arrive.WhatsApp Business has been initiated for direct communication between patients and pharmacists. A total of 10 030 inpatient pharmacy and outpatient pharmacy orders were verified through remote access. 1ISG-009 Table 1Parameter Online refill March 2020 3340 April 2020 9413 May 2020 4990 10 June 2020 7777 Total number of requests during 2019 488 Total number of requests in 2020 25 520 Total shipped 15 March to 10 June 2020 14 618 WhatsApp sent message 14 633 WhatsApp received message 26 613 Orders verified by remote access (outpatient) 4650 Orders verified by remote access (inpatient) 5380 Conclusion and relevanceIn conclusion, the implementation of telepharmacy via the utilisation of medication home delivery services, remote access, and modification of the previous workflow was associated with promising outcomes in terms of efficient, high-quality pharmaceutical care delivery while avoiding medication distribution disturbances as well as containing the spread of the pandemic among staff and patients, thus ensuring their safety during this crisis.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122064272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.430
A. García Robles, Mdm Serrano Martin, MJ Párraga, E. Guerrero Hurtado, P. Polo Montanero, J. P. Poveda Andrés, M. Aguar Carrascosa, A. Gimeno Navarro
{"title":"6ER-006 Paracetamol versus ibuprofen for treatment of persistent ductus arteriosus closure in preterm infants: IBUPAR-Trial","authors":"A. García Robles, Mdm Serrano Martin, MJ Párraga, E. Guerrero Hurtado, P. Polo Montanero, J. P. Poveda Andrés, M. Aguar Carrascosa, A. Gimeno Navarro","doi":"10.1136/ejhpharm-2022-eahp.430","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.430","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116994120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.422
Z. Rodríguez Fernández, S. Llamas Lorenzana, P. González Pérez, X. Casás Fernández, A. Vélez Blanco, C. De Castro Avedillo, JC Sáez Hortelano, R. Varela Fernández, E. Martínez Álvarez, N. Álvarez Núñez, JJ Ortiz de Urbina González
{"title":"5PSQ-101 Medication errors in unit-dose drug distribution system: quality control","authors":"Z. Rodríguez Fernández, S. Llamas Lorenzana, P. González Pérez, X. Casás Fernández, A. Vélez Blanco, C. De Castro Avedillo, JC Sáez Hortelano, R. Varela Fernández, E. Martínez Álvarez, N. Álvarez Núñez, JJ Ortiz de Urbina González","doi":"10.1136/ejhpharm-2022-eahp.422","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.422","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"91 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125076942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：